Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors.
Ontology highlight
ABSTRACT: Developing a potent antiviral agent to combat Coronavirus Disease-19 (COVID-19) is of critical importance as we may be at risk of the emergence of new virus strains or another pandemic recurrence. The interaction between the SARS-CoV-2 spike protein and Angiotensin Converting Enzyme 2 (ACE2) is the main protein-protein interaction (PPI) implicated in the virus entry into the host cells. Spike-ACE2 PPI represents a major target for drug intervention. We have repurposed a previously described protein-protein interaction detection method to be utilized as a drug screening assay. The assay was standardized using Chitosan nanoparticles (CNPs) as the drug and SARS-CoV-2 spike-ACE2 interaction as the PPI model. The assay was then used to screen four natural bioactive compounds: Curcumin (Cur), Ga
SUBMITTER: Emam MH
PROVIDER: S-EPMC11405717 | biostudies-literature | 2024 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA